A modification of the JAM test is necessary for a correct determination of apoptosis induced by FasL+ adherent tumor cells

被引:20
作者
Böhm, C
Hanski, ML
Gratchev, A
Mann, B
Moyer, MP
Riecken, EO
Hanski, C
机构
[1] Free Univ Berlin, Klinikum Benjamin Franklin, Dept Gastroenterol, D-12200 Berlin, Germany
[2] Univ Hosp Benjamin Franklin, Dept Surg, Berlin, Germany
[3] InCell Corp, San Antonio, TX USA
关键词
JAM-test; apoptosis; Fas ligand; tumor; T cell;
D O I
10.1016/S0022-1759(98)00100-8
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Tumor cells from several organs including colon have recently been shown to express Fas ligand (FasL) in vitro and in vivo. The expression, which in some tumours occurs de novo, was suggested to facilitate immune escape of malignant cells by killing tumor-infiltrating lymphocytes via Fas-FasL-induced apoptosis, An argument to support this hypothesis is the detection of tumor cell-induced apoptosis in Jurkat cells (as model T cells) by means of the widely used JAM test. In the present work the validity of this test for the analysis of colon carcinoma cell-mediated apoptosis in Jurkat cells was scrutinized in detail. The presented data show that the JAM test as described previously is prone to false-positive detection of apoptosis, when adherent epithelial cells are used as effecters. Furthermore, three lines of evidence indicated that several FasL(+) colon carcinoma cell lines did not induce detectable apoptosis in Jurkat cells in vitro, We conclude that: (1)The JAM test must be modified for testing DNA fragmentation induced through adherent effector cells and (2) FasL(+) colon carcinoma cells may be unable to induce apoptosis in vitro. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:71 / 78
页数:8
相关论文
共 30 条
  • [1] Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts
    Allison, J
    Georgiou, HM
    Strasser, A
    Vaux, DL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) : 3943 - 3947
  • [2] A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION
    BELLGRAU, D
    GOLD, D
    SELAWRY, H
    MOORE, J
    FRANZUSOFF, A
    DUKE, RC
    [J]. NATURE, 1995, 377 (6550) : 630 - 632
  • [3] Human tumor antigens recognized by T lymphocytes
    Boon, T
    vanderBruggen, P
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (03) : 725 - 729
  • [4] Ehl S, 1996, J IMMUNOL, V156, P2357
  • [5] Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover
    French, LE
    Hahne, M
    Viard, I
    Radlgruber, G
    Zanone, R
    Becker, K
    Muller, C
    Tschopp, J
    [J]. JOURNAL OF CELL BIOLOGY, 1996, 133 (02) : 335 - 343
  • [6] Glass A, 1996, J IMMUNOL, V156, P3638
  • [7] Fas-ligand: Privilege and peril
    Green, DR
    Ware, CF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (12) : 5986 - 5990
  • [8] The role of FasL-induced apoptosis in immune privilege
    Griffith, TS
    Ferguson, TA
    [J]. IMMUNOLOGY TODAY, 1997, 18 (05): : 240 - 244
  • [9] Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
    Hahne, M
    Rimoldi, D
    Schroter, M
    Romero, P
    Schreier, M
    French, LE
    Schneider, P
    Bornand, T
    Fontana, A
    Lienard, D
    Cerottini, JC
    Tschopp, J
    [J]. SCIENCE, 1996, 274 (5291) : 1363 - 1366
  • [10] Activated B cells express functional Fas ligand
    Hahne, M
    Renno, T
    Schroeter, M
    Irmler, M
    French, L
    Bornand, T
    MacDonald, HR
    Tschopp, J
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (03) : 721 - 724